{
    "clinical_study": {
        "@rank": "95871", 
        "arm_group": [
            {
                "arm_group_label": "Mitoxantrone Hydrochloride Liposome", 
                "arm_group_type": "Experimental", 
                "description": "Dose escalation will begin at 6mg/m2 to 16mg/m2,4 weeks apart"
            }, 
            {
                "arm_group_label": "Mitoxantrone ,injection", 
                "arm_group_type": "Active Comparator", 
                "description": "When the dose of experiment drup up 10mg/m2,10mg/m2 of Mitoxantrone as active comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to examine the toxicity profile, maximum tolerated dose (MTD),\n      and pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection."
        }, 
        "brief_title": "Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The trial of the dose escalation method is from the minimum dose until the maximum tolerated\n      dose and every 3 patient is a dose group."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Patients must compliance with the requirements and restrictions listed in the\n             consent form\n\n          -  Patients with Pathology and / or cytologically proven malignant solid tumor\n\n          -  Patients must be 18-70 years old ,both male and female\n\n          -  Failure of standard chemotherapy\n\n          -  Patients have no better choice and may be benefit from the use of anthracyclines\n\n          -  Patients must have Eastern Cooperative Oncology Group (ECOG)Performance Status of 0-2\n\n          -  Objective tumor from the last chemotherapy, biological therapy or other experimental\n             interval  treatment least 4 weeks\n\n          -  Expected survival time \u2265 3 months\n\n          -  Patients agreed to take effective contraceptive measures during the trial\n\n          -  Blood routine, liver and kidney function, cardiac function examination in accordance\n             with the following requirements.\n\n        Exclusion criteria:\n\n          -  Pregnancy and breast-feeding women\n\n          -  Multiple sclerosis\n\n          -  Patients that have histories of ischemic heart disease and heart\n             congestive,arrhythmia that need to be a treatment and significant valvular disease\n\n          -  Patients with heart disease induced by anthracycline\n\n          -  Patients requiring other antineoplastic treatment\n\n          -  Patients with temperature above 38 degrees or active infection that may effects in\n             clinical tests\n\n          -  Patients are allergic to anthracycline and liposomal drugs\n\n          -  Patients are allergic to eggs,egg products,soybean and soybean products\n\n          -  Patients with uncontrolled primary or metastatic brain tumors"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02043756", 
            "org_study_id": "cspcmitlip"
        }, 
        "intervention": [
            {
                "arm_group_label": "Mitoxantrone Hydrochloride Liposome", 
                "description": "6-16mg/m2, IV ,one time  of each 28 day cycle,3 cycles", 
                "intervention_name": "Mitoxantrone Hydrochloride Liposome", 
                "intervention_type": "Drug", 
                "other_name": "2010L04017"
            }, 
            {
                "arm_group_label": "Mitoxantrone ,injection", 
                "description": "10mg/m2, IV ,on day 1 of each 28 day,3 cycles", 
                "intervention_name": "Mitoxantrone", 
                "intervention_type": "Drug", 
                "other_name": "Novantrone"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Mitoxantrone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Mitoxantrone Hydrochloride Liposome Injection", 
        "lastchanged_date": "January 21, 2014", 
        "number_of_arms": "2", 
        "official_title": "Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Solid Tumor", 
        "overall_official": [
            {
                "affiliation": "Cancer Hospital ,Chinese Academy of Mddical Sciences 010-87788701", 
                "last_name": "Yuankai Shi, Ph.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Cancer Hospital ,Chinese Academy of Mddical Sciences 010-87788121", 
                "last_name": "Jianliang Yang, Ph.D", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Cancer Hospital ,Chinese Academy of Mddical Sciences 010-87788701", 
                "last_name": "Xiaohong Han, Ph.D", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "To determination the maximal tolerance dose and dose-limiting toxicity of  Mitoxantrone Hydrochloride Liposome", 
            "safety_issue": "Yes", 
            "time_frame": "3 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02043756"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "CSPC ZhongQi Pharmaceutical Technology Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CSPC ZhongQi Pharmaceutical Technology Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}